Literature DB >> 17656180

Effect of a single vaginal administration of levonorgestrel in Carraguard gel on the ovulatory process: a potential candidate for "dual protection" emergency contraception.

Vivian Brache1, Horacio Croxatto, Regine Sitruk-Ware, Robin Maguire, Juan Carlos Montero, Narender Kumar, Ana Maria Salvatierra, Ana Sofia Tejada, Leila Cochón, María Luisa Forcelledo, Pekka Lahteenmaki, Francisco Alvarez, Anibal Faundes.   

Abstract

OBJECTIVE: The study was conducted to evaluate the effect of Carraguard vaginal gel containing 0.75 mg of levonorgestrel (CARRA/LNG gel) administered in a single dose at different stages of follicle development over subsequent follicle rupture and hormonal levels.
METHOD: Randomized, blinded, cross-over study comparing the effects of a single administration of CARRA/LNG gel or Carraguard (CARRA) gel. Twenty-four healthy women were enrolled in two centers. The gels were administered when the follicle had reached diameters of 12-14, 15-17 and > or =18 mm in eight women each. Volunteers were followed for one treatment, one washout cycle and a second treatment cycle. Follicle rupture or nonrupture was assessed by transvaginal ultrasound. Luteinizing hormone, estradiol and progesterone levels were measured daily for 5 days following treatment, and three times per week until menses.
RESULTS: No follicular rupture within the 5-day period following administration was observed in 74% and 30% of the CARRA/LNG and CARRA gel treatment cycles, respectively, while ovulation was documented in 4% and 61%, respectively. The overall proportion of cycles with lack of follicular rupture or ovulatory dysfunction (follicle rupture preceded by an inadequate LH surge) was 96% for CARRA/LNG and 39% in the CARRA gel cycles.
CONCLUSION: Single vaginal administration of 0.75 mg LNG in CARRA gel in the late follicular phase is effective for interfering with the ovulatory process.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17656180      PMCID: PMC2077845          DOI: 10.1016/j.contraception.2007.04.005

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  26 in total

1.  Vaginal formulations of carrageenan protect mice from herpes simplex virus infection.

Authors:  V R Zacharopoulos; D M Phillips
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

2.  Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial.

Authors:  Helena von Hertzen; Gilda Piaggio; Juhong Ding; Junling Chen; Si Song; György Bártfai; Ernest Ng; Kristina Gemzell-Danielsson; Amindavaa Oyunbileg; Shangchun Wu; Weiyu Cheng; Frank Lüdicke; Alenka Pretnar-Darovec; Rosemary Kirkman; Suneeta Mittal; Archil Khomassuridze; Dan Apter; Alexandre Peregoudov
Journal:  Lancet       Date:  2002-12-07       Impact factor: 79.321

Review 3.  The first uterine pass effect.

Authors:  D De Ziegler; C Bulletti; B De Monstier; A S Jääskeläinen
Journal:  Ann N Y Acad Sci       Date:  1997-09-26       Impact factor: 5.691

4.  Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro.

Authors:  M Baba; M Nakajima; D Schols; R Pauwels; J Balzarini; E De Clercq
Journal:  Antiviral Res       Date:  1988-09       Impact factor: 5.970

5.  Blood levels of levonorgestrel in women following vaginal placement of contraceptive pills.

Authors:  F Alvarez; A Faundes; E Johansson; E Coutinho
Journal:  Fertil Steril       Date:  1983-07       Impact factor: 7.329

6.  Colposcopic evaluation of a vaginal gel formulation of iota-carrageenan.

Authors:  C J Elias; C Coggins; F Alvarez; V Brache; I S Fraser; M Lacarra; P Lähteenmäki; R Massai; D R Mishell; D M Phillips; A M Salvatierra
Journal:  Contraception       Date:  1997-12       Impact factor: 3.375

7.  Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the baby.

Authors:  A J Wilcox; C R Weinberg; D D Baird
Journal:  N Engl J Med       Date:  1995-12-07       Impact factor: 91.245

8.  Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1.

Authors:  R Pearce-Pratt; D M Phillips
Journal:  Biol Reprod       Date:  1996-01       Impact factor: 4.285

9.  Emergency contraception: why can't you give it away? Qualitative findings from an evaluation of advance provision of emergency contraception.

Authors:  Karen Fairhurst; Sue Ziebland; Sally Wyke; Peter Seaman; Anna Glasier
Journal:  Contraception       Date:  2004-07       Impact factor: 3.375

10.  Pituitary-ovarian function following the standard levonorgestrel emergency contraceptive dose or a single 0.75-mg dose given on the days preceding ovulation.

Authors:  H B Croxatto; V Brache; M Pavez; L Cochon; M L Forcelledo; F Alvarez; R Massai; A Faundes; A M Salvatierra
Journal:  Contraception       Date:  2004-12       Impact factor: 3.375

View more
  4 in total

Review 1.  Contraception technology: past, present and future.

Authors:  Regine Sitruk-Ware; Anita Nath; Daniel R Mishell
Journal:  Contraception       Date:  2012-09-17       Impact factor: 3.375

2.  Effect of sexual intercourse on the absorption of levonorgestrel after vaginal administration of 0.75 mg in Carraguard gel: a randomized, cross-over, pharmacokinetic study.

Authors:  Vivian Brache; Horacio Croxatto; Narender Kumar; Regine Sitruk-Ware; Leila Cochón; Veronica Schiappacasse; Irving Sivin; Carla Muñoz; Robin Maguire; Anibal Faundes
Journal:  Contraception       Date:  2008-11-21       Impact factor: 3.375

3.  Vaginally administered PEGylated LIF antagonist blocked embryo implantation and eliminated non-target effects on bone in mice.

Authors:  Ellen Menkhorst; Jian-Guo Zhang; Natalie A Sims; Phillip O Morgan; Priscilla Soo; Ingrid J Poulton; Donald Metcalf; Estella Alexandrou; Melissa Gresle; Lois A Salamonsen; Helmut Butzkueven; Nicos A Nicola; Evdokia Dimitriadis
Journal:  PLoS One       Date:  2011-05-18       Impact factor: 3.240

Review 4.  New and emerging contraceptives: a state-of-the-art review.

Authors:  Luis Bahamondes; M Valeria Bahamondes
Journal:  Int J Womens Health       Date:  2014-02-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.